chronic thromboembolic pulmonary hypertension; pulmonary endarterectomy Background/Purpose: Pulmonary endarterectomy (PEA) is a potentially curative surgical procedure for patients with chronic thromboembolic pulmonary hypertension. The aim of this study is to review our institutional experience with this operation. Methods: We conducted a retrospective review of PEA performed at our institution between January 2005 and December 2013. The measured outcomes were inhospital complications, improvement in cardiac function and exercise capacity, and actuarial survival after PEA. Results: Ten consecutive patients (7 women, 3 men) underwent PEA with a mean age of 59.9 AE 12.9 years. The preoperative New York Heart Association functional class (NYHA FC) for these patients was either Class III (n Z 6) or Class IV (n Z 4). The period from symptom onset to diagnosis was 34.3 AE 37.9 months, and that from diagnosis to operation was 31.4 AE 46.8 months. After PEA, the duration of intensive care unit stay and hospital stay prior to discharge were 9.7 AE 5.7 days and 18.7 AE 7.4 days, respectively. Postoperative complications included reperfusion lung edema (n Z 3) and pneumonia (n Z 1), and all recovered with medical therapy. After a mean follow-up of 48.4 AE 35.1 months, all patients showed marked improvements in their clinical status and were still alive without evidence of disease recurrence.
Introduction
Chronic thromboembolic pulmonary hypertension (CTEPH) is a known sequela of unresolved acute pulmonary embolism, leading to fibrosis and mechanical obstruction of the pulmonary vasculature. It is estimated that 0.57e3.8% of patients with acute pulmonary embolic disease will later develop chronic pulmonary hypertension (PH). 1, 2 If not treated appropriately in the early stages of the disease, PH progresses, leading to right heart failure and death. Pulmonary endarterectomy (PEA) for CTEPH was developed at the University of California, San Diego (UCSD), USA, beginning in the 1970s. 3, 4 As the results have steadily improved, it has become recognized as a standard surgical procedure for this debilitating disorder. 5e7 However, most of these procedures have been done in the United States and Europe, with few reports of PEA in Asian populations. 8e10 This has been attributed to the low incidence of acute pulmonary embolism in Asian populations as compared with Caucasian populations. However, even in Europe, the most relevant challenge remains the diagnosis of CTEPH. 9, 10 Although PEA has become the standard therapeutic approach for CTEPH, it is still a very uncommon procedure in Taiwan and, until now, only a few cases have ever been reported in Taiwanese patients. 11 This article summarizes the efficacy and outcomes of PEA at a single institution in Taiwan over 8 years, emphasizing improvement in functional status, exercise performance, and right heart function seen after the procedure.
Materials and methods

Study protocol
This study is a retrospective analysis of consecutive patients who underwent PEA at the National Taiwan University Hospital, Taipei, Taiwan between January 2005 and December 2013. This study was approved by the Institutional Review Board of the National Taiwan University Hospital. The informed consent requirement was waived.
Surgical candidacy and technique
Surgical candidates for PEA were those with chronic thromboembolic lesions detected within the main lobar or segmental vessels by either a computed tomography angiography of the chest or conventional pulmonary arteriography. Transthoracic echocardiography, lung ventilation and perfusion scanning, and right heart catheterization were used for evaluating surgical feasibility and measuring hemodynamic data preoperatively. Coronary angiography was performed if risk factors for coronary artery disease were present. The indications for PEA were (1) New York Heart Association Functional Class (NYHA FC) III or IV; (2) pulmonary vascular resistance (PVR) higher than 300 dyn s cm À5 prior to PEA; (3) surgically assessable thrombi in main, lobar, or segmental pulmonary arteries; (4) absence of other severe comorbidities. The technique for PEA has already been well established by the UCSD group and is summarized briefly elsewhere. 3 In order to achieve improved visualization and to approach bilateral pulmonary arteries, PEA was performed under cardiopulmonary bypass support through a median sternotomy with the use of aortic cross-clamp and deep hypothermic total circulatory arrest (TCA). The duration of TCA was usually limited to 20 minutes. If longer circulatory arrest was required, it was restarted after 10 minutes of cardioplegia administration for myocardial protection. Once a bloodless surgical field was achieved under TCA, the pulmonary thromboemboli were circumferentially followed down to the segmental and subsegmental branches in each lobe, until a complete endarterectomy of the pulmonary vascular bed was completed. After PEA, circulation with warming was restarted, and other additional proceduresdincluding valve repair or closure of an atrial septal defectdwere performed during this rewarming phase. During surgery, CTEPH was categorized by localization of thromboemboli using the Jamieson classification of pulmonary thromboembolism. 12 Briefly, Jamieson type I (J1 lesion) refers to clot burden in the proximal main and lobar branches with evidence of fresh or subacute thromboembolic material. Jamieson type II (J2 lesion) refers to a more chronic and fibrotic disease in the proximal branches with no fresh clot. Jamieson type III (J3 lesion) refers to disease in the segmental and subsegmental branches only. Jamieson type IV (J4 lesion) refers to no evidence of chronic thromboembolic disease at the time of operation.
Postoperative care
After PEA, all patients were sent to the intensive care unit (ICU) for postoperative care. Patients were monitored with the Swan-Ganz catheters and mechanical ventilation with inotropic support and aggressive diuresis. In order to prevent reperfusion lung edema, we used a protective ventilation strategy (low tidal volume with high positive endexpiratory pressure). In order to treat transient abnormalities of gas exchange and diminish the symptoms of reperfusion lung edema after PEA, oral phosphodiesterase type 5 (PDE5) inhibitors (Viagra; Pfizer Australia Pty Limited, West Ryde, New South Wales, Australia) were initially started via nasogastric tube prior to extubation and continued until 3 months after PEA. The dosage of PDE5 inhibitors started from 25 mg twice daily, and would increase to 25 mg three times per day if the patient could tolerate the treatment without severe adverse effects. For prevention of in situ pulmonary arterial thrombosis and recurrent thromboembolism, these patients were committed to lifelong anticoagulation therapy. After PEA, intravenous low-molecularweight heparin was used prior to extubation and followed by oral warfarin therapy to maintain a target international normalized ratio of around 2.0.
Statistical analysis
Continuous data are expressed as the mean with the standard deviation; nominal values and proportions are represented as numbers and percentages. Comparison between pre-and postoperative variables was performed for continuous variables using the paired two-tailed Student t test. All statistical analyses were performed using SPSS version 17 software (SPSS Inc., Chicago, IL, USA), with p values < 0.05 considered significant.
Results
Preoperative characteristics
Ten patients (7 women, 3 men), with a mean age of 59.9 AE 12.9 years (range, 37e74 years), underwent PEA at our center. Prior to PEA, six patients were classified as NYHA FC III, whereas the other four were NYHA FC IV. The mean duration from disease-specific symptom onset to diagnosis was 34.3 AE 37.9 months (range, 2e129 months), and from diagnosis to operation it was 31.4 AE 46.8 months (range, 0.5e125 months). Eight of the patients underwent right heart catheterization; in the other two patients, the procedure was deemed too risky. One patient with recurrent pulmonary thromboembolic disease has already been bedridden in the ICU for 2 weeks prior to PEA owing to severe shortness of breath, deteriorated cyanosis, and bilateral legs edema. The other patient suffered from obstruction pneumonia with empyema due to the total obstruction of pulmonary arteries prior to PEA. The mean right atrial pressure and mean pulmonary arterial pressure (mPAP) were 12.8 AE 3.2 (range, 8e17) mmHg and 50.6 AE 9.4 (range, 38e70) mmHg, respectively. The mean PVR was 872.4 AE 201.8 (range, 634e1187) dyn s m
À5
, and the mean cardiac output was 3.25 AE 1.06 (range, 1.96e5.07) L min À1 . The baseline patient characteristics are presented in Table 1 .
Operative characteristics and postoperative morbidity
During PEA, the mean time of cardiopulmonary bypass and aortic cross-clamp was 142 AE 48 (range, 46e210) minutes and 86 AE 27 (range, 38e70) minutes, respectively ( Table 2 ). The mean hypothermic TCA time was 25 AE 15 (range, 9e54) minutes. Nine of the patients had proximal pulmonary thromboembolism (J1 and J2 lesions), and one patient had distal pulmonary thromboembolism (J3 lesion). After PEA, the mean duration of ventilator support through tracheal intubation and ICU stay was 6.1 AE 4.8 (range, 1e13) days and 9.7 AE 5.7 (range, 2e18) days, respectively. Four patients (40%) had postoperative complications (3 patients with reperfusion lung edema and 1 patient with pneumonia). These complications were managed with prolonged ventilatory support and medical therapy; all recovered satisfactorily. All 10 patients were discharged home after PEA with a mean hospital stay of 18.7 AE 7.4 (range, 6e30) days.
Clinical outcomes and late follow-up
After discharge, the patients were regularly followed up at an outpatient clinic with noninvasive studies to evaluate the efficacy of PEA 3 months after the surgery. At followup, all patients improved to NYHA FC I (n Z 4) or FC II (n Z 6) (Fig. 1A) . Prior to PEA, one patient was bedridden in the ICU and could not tolerate the 6-minute-walk test (6MWT). Three months after PEA, each patient was able to tolerate the 6MWT. The distance of the 6MWT was significantly increased from 239 AE 123 m preoperatively to 442 AE 102 m postoperatively (p < 0.001) (Fig. 1B) .
Other important studies that reflect the current right and left heart function included BNP (B-type natriuretic peptide) or Pro-BNP blood levels and tricuspid regurgitation peak gradient and left ventricle ejection fraction as measured with transthoracic echocardiography. In our institution, Pro-BNP levels were only available after May 2009. After PEA, serum BNP (n Z 4) significantly decreased from 685.3 AE 342.7 pg/mL to 141.8 AE 118.9 pg/mL (p < 0.05), and Pro-BNP (n Z 6) significantly decreased from 4952.8 AE 4761.2 pg/mL to 483.8 AE 693.9 pg/mL (p < 0.05) (Fig. 1C) . The tricuspid regurgitation peak gradient significantly decreased from 78.2 AE 28.7 mmHg to 26.9 AE 9.9 mmHg (p < 0.001), and the left ventricle ejection fraction significantly increased from 64.5 AE 6.7% to 71.2 AE 5.2% (p < 0.05) (Fig. 1D) .
At the end of March 2014, all patients were still living with a mean follow-up time of 48.4 AE 35.1 (range, 5.1e107.7) months. During the follow-up period, none of the patients reported PH-related symptoms or had evidence of disease recurrence.
Discussion
This retrospective single-institution study presents the preliminary surgical experience for 10 consecutive PEA procedures in CTEPH patients in Taiwan. To our knowledge, this study is the first case series to report on the outcomes of PEA in Taiwanese patients with CTEPH in the English literature.
The true incidence, prevalence, and epidemiology of CTEPH in Taiwan are still largely unknown. However, the higher incidence and prevalence of CTEPH in Caucasians indicates that the factors triggering or influencing the development of CTEPH may be different between Asians and Caucasians; further study and investigation are still needed in this area in the future. 13 Although some large case series reporting PEA results have been published in the past 2 decades, most of the patients in these reports were Caucasian. 8,9,14 PEA could provide dramatic improvements for patients with CETPH; however, the procedure is relatively complex with an inhospital mortality rate about 4.4e16%. 4,14e17 Recently, two case series from Japan and South Korea demonstrated the efficacy and outcome of PEA for Asian patients with CTEPH. In a 20-year period, 77 patients underwent PEA at Chiba University Hospital and its affiliated hospitals. 18 There were 11 (14.3%) inhospital deaths, and the 5-year survival was 84%. Oh et al 19 also reported their PEA results for 16 patients with CTEPH over 12 years in Korea. The inhospital mortality and 5-year survival rates were 12.5% and 76.2%, respectively. In our small study population, all patients receiving PEA were discharged home without any inhospital mortality and were still alive and well without evidence of disease recurrence at the time of publication. Surgical outcome after PEA depends in part on some disease-specific characteristics. For instance, surgery for distal (J3 and J4 lesions) pulmonary thromboembolic disease is still technically demanding and risky, and has worse outcomes when compared with PEA for proximal disease (J1 and J2 lesions), even at an experienced center. 3, 12, 15 The UCSD group reported that patients with distal disease (J3 and J4 lesions) had a higher perioperative mortality rate compared with patients with proximal disease (J1 and J2 lesions). 12 Ogino et al 20 reported that 18.9% of their patients with distal disease required extracorporeal membrane oxygenation support after PEA largely because of residual PH, whereas only 3.9% with proximal disease required extracorporeal membrane oxygenation because of pulmonary bleeding, which resulted from technical problems. In our series, the majority (90%) of our patients had proximal pulmonary thromboembolic disease. After PEA, only four patients had complications (3 patients with reperfusion lung edema and 1 patient with pneumonia), all of which were successfully treated. This underscores our point that proper patient selection and careful postoperative management are as important as surgical technique at a center with limited experience with PEA.
Although CTEPH is a subset of PH potentially cured by PEA, CTEPH is still underdiagnosed and commonly not properly managed. According to the recent report from the European registry, the main challenges to the treatment of CTEPH are the low awareness of physicians, underdiagnosis, and late diagnosis. 9 In our study, the mean duration from symptom onset to confirmed diagnosis and from diagnosis to operation were both longer than 30 months. In order to provide the best therapeutic options for patients with CTEPH, it is important to increase public awareness of this disease and thereby help avoid unnecessary delays in diagnosis and treatment.
Patients with CTEPH are severely clinically compromised and require oxygen treatment for severe oxygen desaturation and right heart decompensation as a result of ventilationeperfusion mismatch and PH caused by organized thrombi obstructing the pulmonary arteries. The mechanical obstruction of pulmonary thromboemboli and the thickening pulmonary endothelium can be removed simultaneously through PEA, resulting in a significant reduction of PH immediately after surgery. Clinical symptoms, functional status, and exercise capacity can have significant sustained improvement after PEA. Unlike the prompt pulmonary hemodynamic improvements after PEA, however, it takes from 6 months to 2 years to achieve improvements in gas exchange in pulmonary vessels after PEA. 21, 22 The reasons for the delayed recovery of gas exchange after PEA are multifold: these include a temporal ventilationeperfusion abnormality and restrictive pulmonary functional impairment in response to surgical trauma, diffusion limits in response to pulmonary edema, and steal of perfusion from high-resistance nonobstructed segments by low-resistance newly perfused pulmonary segments. 21, 22 This discrepancy between excellent functional status recovery and slow improvement in gas exchange is very unique, and results in some patients with NYHA FC I or II after PEA still requiring oxygen therapy. 18, 20, 23 Ishida et al 18 reported that although 92% of patients returned to NYHA FC I or II after PEA, 37% of them still depended on home oxygen therapy. In order to shorten this discrepant period between pulmonary hemodynamics and gas exchange, the oral PDE5 inhibitors were prescribed to eight of our patients who showed signs of inadequate oxygenation or symptoms of reperfusion lung edema after PEA. In this study, all of our patients were NYHA FC III or IV, and 90% of them required oxygen therapy prior to PEA. After PEA, all patients were NYHA FC I or II, and 90% of them were weaned off oxygen prior to discharge. The only patient who required oxygen therapy after discharge was a 74-year-old woman who suffered from recurrent pulmonary thromboembolic disease. She had already undergone pulmonary thrombectomy 12 years previously and developed recurrent CTEPH with J2 lesions (Fig. 2A) . She was admitted to our ICU for severe desaturation and cardiac decompensation preoperatively. A complete PEA with dissection into subsegmental branches was achieved, and the mechanical obstruction of pulmonary thromboemboli and the thickening pulmonary intima were both removed simultaneously ( Fig. 2B and 2C ). Her postoperative course was uneventful; she was discharged home 25 days after PEA but relied on oxygen support during sleep. Three months after discharge, she was weaned off oxygen support successfully with adequate oxygenation during exercise, and the consequent chest computed tomography demonstrated that the pulmonary arteries regained patency (Fig. 2D) .
In one small double-blind, placebo-controlled pilot study, Suntharalingam et al 24 reported that long-term sildenafil treatment could significantly improve the functional class and PVR in patients with inoperable CTEPH. Until now, however, there is no large series report to demonstrate that the oral sildenafil treatment has clinical benefits on the transient abnormalities of gas exchange after PEA in patients with CTEPH. Although the size of our study population is small, our results imply that the oral PDE5 inhibitor may improve abnormal gas exchange and shorten the duration of oxygen dependence after PEA. In the future, a large randomized control trial is needed to confirm our preliminary findings.
CTEPH is considered Group IV based on the clinical classification of PH derived from the Fourth World Symposium on PH held in 2008. 5 The major vessel obstruction and remodeling combined with small vessel arteriopathy in CTEPH were shown to be histologically indistinguishable from the classical arteriopathy observed in pulmonary artery hypertension (PAH). Over the past decade, a wide variety of new medical therapies have become available for the treatment of PAH that have significantly improved patient survival compared with traditional treatments. These PAH-specific therapies are increasingly being used in patients with CTEPH because of its morphological similarities with PAH and have resulted in delayed referral for surgery in CTEPH patients. The UCSD group reported that nearly 45% of the patients with operable CTEPH were treated by at least one of these PAH-specific drugs prior to referral to a center experienced in PEA. 8 Unlike Idiopathic PAH or PAH related to connective tissue disease, however, there is a lack of large randomized control clinical trial data supporting the efficacy and survival benefit of these PAH-specific drugs for patients with operable CTEPH. 6 PEA continues to be one of the gold standard therapies for CTEPH and the only potentially curative treatment. 23, 25 Moreover, operable CTEPH patients treated with PEA have a better long-term survival than those deemed inoperable and treated with medical therapy alone. 26 Therefore, caution should be taken when CTEPH patients are treated with PAH-specific drugs prior to referral to and evaluation in a PEA center.
The issue of operability in CTEPH continues to be a source of discussion and debate. The quality of imaging tests preoperatively, the experience of the surgeon and staff, the integrated patient support system provided by the institution, the disease category and severity of PH, and the patient's comorbidities all impact the overall surgical outcome. Without surgery, the prognosis of CTEPH is dismal. Riedel et al 27 reported that the 5-year survival is <30% if mPAP exceeds 30 mmHg, and is as low as 10% if mPAP exceeds 50 mmHg. Therefore, there is a general consensus that patients suspected of having CTEPH should be referred to an experienced center for surgical evaluation because PEA is a potential curable therapy for this devastating disorder. 6, 7, 26 Although our study population is small and our surgical experience is limited, we hope that increased awareness of CTEPH and PEA among physicians in Taiwan as well as the acceptable surgical morbidity and satisfactory postoperative outcome at our center will encourage early referral of potential surgical candidates.
This study is limited by its single-institution, retrospective nature. Moreover, although this case series is the largest to date in Taiwan, the sample size is still too small over such an extended period, averaging fewer than two patients per year. An increased number of patients is needed to better determine the long-term efficacy among Taiwanese patients of this highly technique-dependent surgery.
In conclusion, with appropriate patient selection, multidisciplinary team cooperation, and meticulous postoperative management, safe and effective PEA can be conducted in Taiwanese patients with operable CTEPH. 
